Abstract: Background: Internal malignancies such as breast cancer, as well as their treatment can often result in skin changes. oBjective: To assess the prevalence of dermatological complaints in patients who are undergoing oncological treatment for breast cancer in a hospital in Tubarão, Santa Catarina, Brazil. Methods: Observational, cross-sectional study, from October 2015 to February 2016 in which 152 patients with the diagnosis of breast cancer, undergoing treatment with chemotherapy, radiotherapy, hormone therapy and/or surgery, were interviewed and completed a research protocol developed by the author. results: The treatment of breast cancer was associated with dermatological complaints in 94.1% of the interviewed, being with hair loss the most frequent, present in 79.6% of the sample, followed by nail changes (56%). Patients with lighter skin phototypes (I, II and III) had a lower risk (p=0.045) of developing skin changes when compared to darker phototypes. Radiation therapy (p=0.011) and oncological surgery (pFisher=0.004) were statistically significant when related to skin changes. study liMitations: Inherent to the design of the study, as well as recall bias. conclusions: It was found that most patients diagnosed with breast cancer showed dermatologic manifestations during the proposed cancer treatment. Patients undergoing radiotherapy and surgery showed skin changes with greater statistical significance. 
INTRODUCTION
Breast cancer is the second most frequent type of cancer in the world and the most common among women, either in developing or developed countries and in Brazil it has an estimated gross rate of 57,960 new cases for 2016. 1 It affects more frequently women around 50 years of age. However, in the last decades, it was observed an increase of the global incidence of this malignancy, including in younger age groups, as well as a mortality rate that is also growing in the country, what can be explained by the fact that the disease is still diagnosed in advance stages. 2 Thus, the importance of researches on the primary prevention of this malignancy and its interventions is clear.
1
As treatment modalities for this malignancy, there is surgery and radiotherapy for locoregional treatment, besides chemotherapy and hormone therapy for systemic treatment. 3 Internal malignancies such as breast cancer can frequently cause cutaneous manifestations due to direct effects, i.e., invasion of the skin by a tumor or its metastasis, or by indirect effects that trigger cutaneous signs and/or symptoms. 4 It is also known that cancer treatment itself with chemotherapy and radiotherapy, for example, are also related to the appearance of multiple side effects on the on the skin of cancer patient. 5, 6 Besides the skin itself, hair and nails, complex adnexal structures, indirectly influenced by the physiological state of the patient, can also be affected by internal malignancies, as well as by their treatment. 
This research was submitted to the Committee of Ethics in
Research with Humans and was approved under the protocol number 1.541.235.
RESULTS
The study sample was comprised of 152 patients. All members were female, with a mean age of 53.32 years (standard deviation = 12.956) and had the diagnosis of breast cancer followed at Hospital Nossa Senhora da Conceição. All patients had been submitted to treatments as chemotherapy, radiotherapy, hormone therapy and/or surgery. Table 1 shows all the sociodemographic data of the population interviewed.
Regarding the histologic type of the tumor, the most frequent was the invasive ductal carcinoma in 134 patients, what corresponds to 88.2% of the cases, followed by the invasive lobular carcinoma, as shown in table 2.
All participants had already gone through or were undergoing a treatment regimen for breast cancer when interviewed for this study. The most frequent treatment among patients of the sample was chemotherapy, with 129 (84.9%) patients. The second most common treatment was surgery, in 127 (83.5%) women, followed by hormone therapy in 93 (61.2%), and lastly radiotherapy in 86 (56.6%) patients.
During the treatment for breast cancer, 143 (94.1%) participants had some kind of dermatological complaint, being hair loss the most frequent change seen in 121 (79.6%) patients. Table 3 shows the frequency of dermatological complaints according to each treatment.
Besides that, 34 (22.4%) patients reported the presence of a local dermatological change at the moment of diagnosis of the malignancy. Fifteen (9.9%) patients referred mammary retraction, 14 (9.2%), nipple inversion, 4 (2.6%), breast with an "orange peel" aspect and 3 (2.0%), extension of the neoplasia underlying skin.
From the data analysis we observed that the patients that underwent radiotherapy had more frequent dermatological complaints, which was statistically significant (PR:1.13; CI95%:1.03 to 1.23; p = 0.011). In the same way, surgery was a factor also associated to dermatological changes. Patients who underwent surgery had a 20% chance of dermatological changes (PR:1.24; CI95%:1.02 to 1.54;
Chemotherapy (p = 0.138), hormone therapy (p = 0.311) and histological type of the tumor (p = 0.288) were not statistically significantly frequently associated to dermatological manifestations.
The most frequent skin phototype according to Fitzpatrick cancer, what could be explained by the fact that a higher schooling is related to higher chances of the patient to undergo clinical and radiographical examination of the breasts, allowing for earlier diagnosis and treatment. 14, 16 Despite family history in first degree relatives being considered a well-established risk factor for breast cancer, increasing the relative risk two-fold, of the study group, only 19.1% had a positive family history. 17 In addition, this seems to be the risk factor with the greatest impact regarding the encouragement for preventive practices as performing mammograms and routine gynecological examinations.
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The prevalence of invasive ductal carcinoma was the highest, corresponding to 88.2% of the patients, with a profile similar to other studies.
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Hochman B et al 24 note in their research that the darker the skin phototype according to Fitzpatrick, the higher the tendency to develop fibroproliferative scars, classified in keloid, hypertrophic and mixed scars. The objective of this study was not to specify the type of scar reported by the patients but we observed a significant association (p = 0.046) between skin phototype VI and the development of scars, thus supporting data already present in the literature.
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Andrew P et al 13 , in their systematic review on cutaneous reaction related to the use of tamoxifen in breast cancer, reported that nearly 20% of the patients had cutaneous changes at any point during treatment, ranging from more common manifestations as rubor to other potentially fatal as Stevens-Johnson syndrome. In the same way, we observed in the present study a frequency of 69% of dermatological changes that occurred during hormone therapy.
Moreover, the use of hormone therapy was associated to the appearance of hot flushes in 51,6% of the patients, consistent with the study by Leite et al. 25 , found it to be the main side effect of the use of tamoxifen in patients being treated for breast cancer.
Cutaneous side effects due to radiotherapy are common and sometimes severe, even leading to reduce the treatment duration. 26, 27 These effects can be acute or chronic. Acute effects are those that occur hours to weeks after exposure to radiation and are characterized by erythema, edema, scaling, hyperpigmentation and local alopecia. Chronic effects tend to be more severe and occur months to years after the exposure and can present as ulcers, necrosis and fibrosis. 28 Hu et al. 29 observed that 95.1% of the women with cancer receiving radiotherapy as adjuvant treatment had acute cutaneous reactions to the radiation. In the same way, this study obtained a similar frequency, in which 97.6% of the patients exposed to radiation had dermatological changes. The most reported complaint was erythema of the breast, followed by hyperpigmentation, present in 73.2% and 64% of the patients treated with radiation, respectively, what is in contrast with another study that assessed the effects of post-operatory radiotherapy, in which hyperpigmentation and fibrosis were detected in 52% of the patients. 30 The study by Hu et al. 29 also demonstrated hyperpigmentation on the breast of women treated with radiotherapy, as well as xerosis, complaints reported in 20.9% of the irradiated patients in this study. This is due to the fact that the skin, an organ that is continually renewed, is highly susceptible to radiation injury, leading to acute and late cutaneous changes, and therefore, radiotherapy is associated to a higher prevalence of those (p = 0.011). 31 Moreover, Patani et al 32 , suggest in a study that patients submitted to surgery and adjuvant radiotherapy had a worse cosmetic outcome when compared to the patients that did not undergo radiotherapy.
On the other hand, chemotherapy is also related to multiple dermatological changes such as alopecia, erythema, itch, xerosis, acne, hypersensitivity reactions, local desquamation and nail changes and, because its target are proliferating cells, the dermatological reactions are the most common side effects in cancer patients treated with chemotherapy. 33 This study found that the complaint of hair loss was the most frequent event related to chemotherapy, reported by 117 patients. This is considered the first dermatological manifestation from the use of antineoplastic drugs, appearing straight after the beginning of the treatment and occurs due to the trichorrhexis, fragmentation, reduction in the diameter and depigmentation of the hair. 33 Nail changes are also considered frequent.
Heidary et al 34 , observed them in their update in around 10 to 15%
of the patients treated with chemotherapy, typically as late events, that usually appear between 4 to 8 weeks of treatment. Calderón et al 35 , in a comparative study performed in Mexico, evaluated the frequency of nail changes secondary to chemotherapy with taxanes and observed that 56% of the patients developed such changes, the more common being melanonychia, Beau's lines, Muehrcke's lines and longitudinal streaks. Other nail changes induced by chemotherapy are subungual hematoma and onycholysis, with the clinical presentation influenced by the duration of treatment and the degree of toxicity of each antineoplastic drug. 36 Winther et al 37 evaluated nail changes in patients with metastatic breast cancer during treatment with docetaxel, and their study shows that 55% of the patients had some degree of nail changes. In this study, the data were also in agreement with the literature, and we observed that approximately 52% of the patients treated with chemotherapy reported some nail change. Other changes related to chemotherapy were seen in the study by Kang et al 38 , in which the complaint of dry skin in patients being treated for breast cancer was reported by 57.9% of the patients, a higher frequency than that found in this research, which was 12.6%.
Regarding oncological surgery of the breasts, the presence 
CONCLUSION
This research contributes for the identification of the profile of patients with the diagnosis of breast cancer, which as female, are mostly in the age group of 40-69 years, are married, retired or pensioners and have incomplete middle school. Besides, the evaluation of the prevalence of dermatological complaints in these patients reveals that most had some kind of dermatological change during the treatment, statistically significant for the patients submitted to radiotherapy and surgery. These findings allow the elaboration of intervention strategies in order to minimize potential side effects from the treatment, be it chemotherapy, hormone therapy, radiotherapy and/or surgical. It is worth highlighting that a large number of interviewees reported dermatological changes at the time of diagnosis of cancer, showing that, in these cases, the diagnosis was not made early.
Therefore, we alert for the importance in continuing studies regarding this subject, in order to improve the quality of life regarding to the dermatological aspects of the patients being treated for breast cancer.
As limitations of this study, we can cite those inherent to the study design, as well as recall bias. q
